Uy Ear
Stock Analyst at Mizuho
(3.22)
# 1,072
Out of 4,761 analysts
58
Total ratings
43.75%
Success rate
17.78%
Average return
Main Sectors:
Stocks Rated by Uy Ear
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $19 → $20 | $13.02 | +53.61% | 13 | Jan 7, 2025 | |
| QURE uniQure | Maintains: Neutral | $7 → $20 | $12.84 | +55.76% | 4 | Dec 19, 2024 | |
| RLMD Relmada Therapeutics | Downgrades: Neutral | $23 → $1 | $0.30 | +238.98% | 1 | Dec 5, 2024 | |
| ALKS Alkermes | Maintains: Outperform | $35 → $40 | $35.32 | +13.25% | 5 | Nov 13, 2024 | |
| SAGE Sage Therapeutics | Maintains: Neutral | $18 → $16 | $7.31 | +118.88% | 2 | Jul 19, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | $40 | $19.24 | +107.90% | 1 | May 24, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $145 → $179 | $106.28 | +68.42% | 5 | May 17, 2024 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Neutral | $25 → $21 | $19.95 | +5.26% | 10 | May 9, 2024 | |
| EOLS Evolus | Maintains: Buy | $20 → $23 | $13.99 | +64.40% | 3 | Mar 8, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Neutral | $116 → $140 | $120.69 | +16.00% | 10 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $40 | $162.30 | -75.35% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $2.06 | +385.44% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $3 | $0.68 | +341.18% | 2 | Mar 1, 2023 |
Arcutis Biotherapeutics
Jan 7, 2025
Maintains: Outperform
Price Target: $19 → $20
Current: $13.02
Upside: +53.61%
uniQure
Dec 19, 2024
Maintains: Neutral
Price Target: $7 → $20
Current: $12.84
Upside: +55.76%
Relmada Therapeutics
Dec 5, 2024
Downgrades: Neutral
Price Target: $23 → $1
Current: $0.30
Upside: +238.98%
Alkermes
Nov 13, 2024
Maintains: Outperform
Price Target: $35 → $40
Current: $35.32
Upside: +13.25%
Sage Therapeutics
Jul 19, 2024
Maintains: Neutral
Price Target: $18 → $16
Current: $7.31
Upside: +118.88%
Cartesian Therapeutics
May 24, 2024
Initiates: Buy
Price Target: $40
Current: $19.24
Upside: +107.90%
Sarepta Therapeutics
May 17, 2024
Maintains: Buy
Price Target: $145 → $179
Current: $106.28
Upside: +68.42%
ACADIA Pharmaceuticals
May 9, 2024
Maintains: Neutral
Price Target: $25 → $21
Current: $19.95
Upside: +5.26%
Evolus
Mar 8, 2024
Maintains: Buy
Price Target: $20 → $23
Current: $13.99
Upside: +64.40%
Neurocrine Biosciences
Feb 8, 2024
Maintains: Neutral
Price Target: $116 → $140
Current: $120.69
Upside: +16.00%
Jun 7, 2023
Maintains: Buy
Price Target: $36 → $40
Current: $162.30
Upside: -75.35%
Mar 17, 2023
Reiterates: Buy
Price Target: $10
Current: $2.06
Upside: +385.44%
Mar 1, 2023
Maintains: Buy
Price Target: $5 → $3
Current: $0.68
Upside: +341.18%